PMID- 31235127
OWN - NLM
STAT- MEDLINE
DCOM- 20191218
LR  - 20191218
IS  - 1878-0334 (Electronic)
IS  - 1871-4021 (Linking)
VI  - 13
IP  - 3
DP  - 2019 May-Jun
TI  - A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used 
      for the treatment of type 2 diabetes mellitus.
PG  - 2001-2008
LID - S1871-4021(19)30115-8 [pii]
LID - 10.1016/j.dsx.2019.04.035 [doi]
AB  - Sodium-glucose co-transporter 2 (SGLT2) inhibitors are the latest class of drugs 
      to be introduced for the treatment of type 2 diabetes mellitus (T2DM). They 
      reduce hyperglycemia by increasing urinary glucose excretion and exert favorable 
      effects beyond glucose control with consistent body weight, blood pressure, and 
      serum uric acid reductions. Empagliflozin is a potent SGLT2 inhibitor used to 
      improve glycemic control in adults with T2DM. It has the highest SGLT2 
      specificity among all the clinically used or currently tested SGLT2 inhibitors. 
      Low risk of hypoglycemia, absence of weight gain and demonstrated cardiovascular 
      risk reduction support its consideration as a first line medication in addition 
      to metformin for patients with T2DM and cardiovascular disease. Mostly reported 
      adverse events are genital mycotic infections, while urinary tract infections and 
      events linked to volume depletion are rather rare. This review covers the 
      complete information on empagliflozin including the history of its development, 
      synthesis, pharmacology and different methods which have been reported for its 
      analysis.
CI  - Copyright (c) 2019 Diabetes India. Published by Elsevier Ltd. All rights reserved.
FAU - Chawla, Gita
AU  - Chawla G
AD  - Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and 
      Research, Jamia Hamdard (Deemed to be University), Hamdard Nagar, New Delhi, 110 
      062, India. Electronic address: gchawla@jamiahamdard.ac.in.
FAU - Chaudhary, Krishna Kr
AU  - Chaudhary KK
AD  - Department of Pharmaceutical Chemistry, School of Pharmaceutical Education and 
      Research, Jamia Hamdard (Deemed to be University), Hamdard Nagar, New Delhi, 110 
      062, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190426
PL  - Netherlands
TA  - Diabetes Metab Syndr
JT  - Diabetes & metabolic syndrome
JID - 101462250
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/*therapeutic use
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Glucosides/*therapeutic use
MH  - Humans
MH  - Prognosis
MH  - Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
EDAT- 2019/06/27 06:00
MHDA- 2019/12/19 06:00
CRDT- 2019/06/26 06:00
PHST- 2019/02/16 00:00 [received]
PHST- 2019/04/22 00:00 [accepted]
PHST- 2019/06/26 06:00 [entrez]
PHST- 2019/06/27 06:00 [pubmed]
PHST- 2019/12/19 06:00 [medline]
AID - S1871-4021(19)30115-8 [pii]
AID - 10.1016/j.dsx.2019.04.035 [doi]
PST - ppublish
SO  - Diabetes Metab Syndr. 2019 May-Jun;13(3):2001-2008. doi: 
      10.1016/j.dsx.2019.04.035. Epub 2019 Apr 26.